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Schizophrenia is a mental disorder that is characterized by various abnormal symptoms. 
Previous studies indicate decreased expression of phospholipase C-β1 (PLC-β1) in
the brains of patients with schizophrenia. PLC-β1-null (PLC-β1−/−) mice exhibit multiple 
endophenotypes of schizophrenia. Furthermore, a study of PLC-β1 knockdown in
the medial prefrontal cortex of mice has shown a specific behavioral deficit, impaired 
working memory. These results support the notion that disruption of PLC-β1-linked 
signaling in the brain is strongly involved in the pathogenesis of schizophrenia. In this 
review, we broadly investigate recent studies regarding schizophrenia-related behaviors 
as well as their various clinical and biological correlates in PLC-β1−/− and knockdown 
mouse models. This will provide a better understanding of the pathological relevance of 
the altered expression of PLC-β1 in the brains of patients with schizophrenia. Evidence 
accumulated will shed light on future in-depth studies, possibly in human subjects.
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inTRODUCTiOn
Schizophrenia-Related Phenotypes
Schizophrenia is generally characterized by genetic and neurofunctional abnormalities and classified 
into three major abnormal symptoms – positive, negative, and cognitive symptoms (1–6). Positive 
symptoms are those that are present in people with schizophrenia, such as delusions, hallucinations, 
thought disorder, and paranoia (7), whereas negative symptoms are deficits of normal emotional 
or of other thought processes such as flat affect, avolition, and social withdrawal (8). Cognitive 
symptoms refer to the difficulties with concentration and memory; examples include short- and 
long-term memory deficits as well as deficits in attention, planning, and abstract thinking (9–11).
Pathogenesis of Schizophrenia
The pathogenesis of schizophrenia has been previously reported to arise from specific neuronal 
abnormalities in several brain regions including prefrontal cortex (PFC) (12–14). Neural mechanisms 
underlying schizophrenia symptoms in several brain areas have been explained by abnormalities in 
the dopaminergic (15, 16), serotonergic (17, 18), muscarinic (19–22), and glutamatergic signaling 
(23–25). Of the many mechanisms, the phosphoinositide (PI) signaling, one of the major G-protein-
linked pathways operating in the central nervous system (CNS), seems to be a point of convergence 
for all signaling pathways mentioned above (26, 27). PI signaling pathways are impaired in specific 
brain regions of patients with neurological (28–31) and psychiatric disorders (32, 33). Altered activ-
ity in PI signal pathways has been implicated in impaired cognition, mood, and abnormal behaviors, 
which is associated with mental disorders including schizophrenia (34, 35).
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Pi Signaling
PI signaling involves PI-specific phospholipase C (PLC) (36, 
37) (Figure  1). PLC hydrolyzes phosphatidylinositol 4,5-bis-
phosphate (PIP2) to produce a pair of second messengers, 
diacylglycerol (DAG), and inositol 1,4,5-trisphosphate (IP3) 
(38). In general, DAG activates protein kinase C (PKC), 
whereas IP3 mobilizes Ca2+ from the intracellular endoplasmic 
reticulum (ER) stores to the cytoplasm (39). PLC-β is one of 
the three subtypes of PLC and is distinguished from PLC-γ 
and PLC-δ by structure and activation mechanisms (40, 41). 
PLC-β acts through G protein-dependent pathways, and Gq/
PLC-β pathway is readily activated by specific neurotransmit-
ter receptors such as the M1, M3, and M5 muscarinic acetyl-
choline receptors (mAChRs), the group 1 and 5 metabotropic 
glutamate receptors (mGluRs), and the 2A and 2C subtype 
of serotonergic receptors (5-HT2AR and 5-HT2CR) (42–46). 
Protein purification and molecular cloning have identified 
four PLC-β isoforms: PLC-β1, PLC-β2, PLC-β3, and PLC-β4 
(47, 48). Interestingly, each PLC-β isoenzyme has a unique 
distribution pattern in the brain (49). PLC-β1 expression is 
relatively abundant in the cerebral cortex although it is widely 
distributed in many brain areas (45, 49). PLC-β2 is mainly 
expressed in the white matter, indicating that its expression 
is in non-neuronal cells (49). PLC-β3 expression is very low 
throughout the brain (50). Finally, PLC-β4 is highly expressed 
in the cerebellum and medial septum but is almost negligible 
in the hippocampus (49–51).
Abnormal PLC-β1 expression has been detected in the brains 
of patients with schizophrenia (52–54). A decrease of PLC-β1 
expression in the dorsolateral prefrontal cortex (DLPFC) of 
the brains of patients with schizophrenia might account for the 
possible pathogenic involvement of PLC-β1 in schizophrenia 
patients (54).
FiGURe 1 | Phospholipase C signaling in neuronal cells. Phospholipase 
C (PLC) cleaves phosphatidylinositol 4,5-bisphosphate (PIP2), a membrane 
phospholipid, to generate two second messengers, inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 is water soluble, 
diffusing through the cytosol to bind to and open a ligand-gated Ca2+ 
channel, such as ryanodine receptor (RyR) in the endoplasmic reticulum (ER). 
Thus, stimulation of a receptor (R) linked to this G-alpha (G) is a way to 
increase Ca2+ inside the cytosol. DAG is lipid soluble and stays in the 
membrane. It activates protein kinase C (PKC), which, like protein kinase A 
(PKA), phosphorylates particular target proteins.
In this review, PLC-β1 signaling pathways, especially their 
hypofunction will be discussed in relation to the pathogenesis 
of schizophrenia-like symptoms in the rodent medial prefrontal 
cortex (mPFC) as well as their hypofunction in patients with 
schizophrenia associated with human DLPFC.
PLC-β1 in SCHiZOPHReniA SYMPTOMS
The association of the PLC-β1 with schizophrenia symptoms has 
been addressed by behavioral studies in PLC-β1−/− mice (55–59). 
It has been well established that schizophrenia-like animal mod-
els exhibit hyperlocomotion (56, 57, 60–64). In the open-field 
test, for example, PLC–β1−/− mice have shown an increase in 
locomotor activity (56, 57), a phenotype which was also exhibited 
in mice with a defect in PLC–β1-relevant signaling. For instance, 
M1 mAChR knockout results in hyperlocomotion in mice (63, 
64), whereas mice lacking M3 and M5 mAChRs show normal 
locomotor activity (65, 66).
Abnormal social behaviors are regarded as one of the negative 
symptoms in schizophrenia patients. In mice, barbering behavior, 
also known as whisker trimming, seems to reflect a cooperative 
social activity and social dominance (67). Interestingly, PLC–
β1−/− mice show a deficit in barbering behaviors, suggesting that 
PLC–β1 signaling is required for normal social interaction and 
dominance (56). In addition, the relevance of the lack of nesting 
behaviors to negative symptoms in patients with schizophrenia 
has been demonstrated (68, 69). Nest building in mice may 
represent activities of daily living (70) and a cooperative activity 
in rodent social behavior (68). Deficits in nest building are related 
to self-neglect (56) and social withdrawal (71). PLC–β1−/− mice 
also display significant nesting deficits, addressing negative-like 
symptoms in rodents.
The lack of sociability is also regarded as a negative symptom 
in schizophrenia patients (72, 73). A three-chamber procedure 
was previously used to evaluate sociability by assessing the time 
spent in each chamber of three divided areas. One area contains 
a conspecific, but the other area does not. If a mouse spends more 
time in the chamber with a conspecific, it has higher sociabil-
ity (74). This procedure has been complemented by measuring 
sniffing time because sniffing time is more accurate than time in 
chamber when evaluating sociability (59). The total sniffing time 
around either a mouse or an object was scored. If the time spent 
sniffing around an unfamiliar conspecific was greater than an 
inanimate object, this is indicative of higher sociability. PLC-β1+/+ 
mice showed normal sociability as they spent more time sniffing 
around an unfamiliar conspecific than an inanimate object. On the 
contrary, sniffing time around both a conspecific and inanimate 
object was decreased in PLC-β1−/− mice. Consequently, PLC-
β1−/− mice have lost their interest in the novelty of an unfamiliar 
conspecific, demonstrating impaired sociability (59).
Cognitive impairment is a core feature of three abnormal 
symptoms that contribute to the morbidity of schizophrenia. Of 
cognitive symptoms, sensorimotor gating is essentially a protec-
tion mechanism against sensory information overload (75). A 
disruption of prepulse inhibition (PPI) is a frequently used trans-
lational model of abnormal sensorimotor gating (76). The PPI 
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deficits have been detected in some neuropsychiatric disorders 
including schizophrenia (77–84). Therefore, PPI may at least in 
part be predictive of certain cognitive functions in schizophrenia 
(84). Furthermore, PLC-β1−/− mice also display impaired PPI 
in acoustic startle response (56, 57). Given that schizophrenia 
patients and PLC-β1−/− mice show impairment in PPI, a measure 
of sensorimotor gating, PLC-β1 signaling pathways seem to be 
required for normal sensorimotor gating function.
Impaired working memory is considered as a core cognitive 
deficit in schizophrenia (85, 86). Delayed non-match to samples 
(DNMTS) T-maze and Y-maze task have been commonly used 
to measure working memory function (87, 88). PLC-β1−/− mice 
exhibit an impairment of working memory in the DNMTS T-maze 
and Y-maze task (56, 58). Based on the working memory deficits 
in PLC-β1−/−, PLC-β1 may be a potential target of pharmaceutical 
intervention to treat cognitive symptoms in schizophrenia.
HUMAn DLPFC AnD RODenT mPFC
Working memory deficits have been previously reported in a 
number of neurological and psychiatric disorders including 
schizophrenia (89–91). Previous studies from human behavioral 
and functional neuroimaging data during working memory tasks 
have described deteriorated activation of the DLPFC in patients 
with schizophrenia (92–94). The human DLPFC, therefore, is 
important for the working memory process (95, 96). Signals 
associated with working memory are reduced in the DLPFC 
of patients with schizophrenia (97, 98). Additionally, deficits 
in working memory have been shown in human brain injury 
patients with damage in DLPFC (99, 100). A decrease of both 
glucose utilization and blood flow during working memory tasks 
have been observed in the DLPFC of patients with schizophrenia 
(94, 101–104). Using electroencephalography (EEG) during a 
working memory test, abnormal brain oscillatory activity has 
been reported in the frontal theta (4–8 Hz) and alpha (8–12 Hz) 
frequencies in patients with schizophrenia (105, 106). Human 
EEG recordings have further revealed abnormal circuitries 
between the PFC and other brain regions in schizophrenia, such 
as the temporal lobe and subcortical limbic structures, suggesting 
that functional connectivity between the PFC and other brain 
regions play some role in the pathogenesis of schizophrenia 
(107–109). It has been supported by evidence that alterations in 
synchronized brain oscillation reflect neuronal changes that lead 
to schizophrenia (110, 111).
The mouse mPFC is thought to have anatomical and functional 
homology with the DLPFC in human being (38, 112–114). The 
mouse mPFC consists of prelimbic (PL) and infralimbic (IL) corti-
ces (38, 112–114). The mouse mPFC receives indirect projections 
from the dorsal hippocampus (dHPC) and direct afferent inputs 
from the ventral hippocampus (vHPC) (115, 116). The mouse 
mPFC has reciprocal connections with the amygdala and other 
subcortical limbic structures (117). Theta frequency synchrony 
between the mPFC and dHPC, and/or beta (13–30 Hz) frequency 
synchrony between the mPFC and mediodorsal thalamic nucleus 
(MD) are required for working memory (13, 118).
Both cytotoxic lesions and acute inactivations in the rodent 
mPFC are able to induce most schizophrenia phenotypes 
including positive, negative, and cognitive-like symptoms, as well 
as working memory deficits (119, 120). It is also worth noting that 
mPFC deficits represent a key component of the pathophysiology 
in patients with schizophrenia (14, 121).
The shRNA-mediated silencing of PLC-β1 in the mPFC, a 
mouse model that mimics the decrease of PLC-β1 in the DLPFC 
of patients with schizophrenia, causes an impairment in working 
memory (59). This effect is specific to working memory; mPFC-
specific PLC-β1 knockdown does not have an effect on other 
behaviors relevant to schizophrenia-related endophenotypes 
characteristic of PLC-β1−/− mice, such as locomotion, social 
behaviors, and sensorimotor gating (59).
PLC-β1 SiGnALinG PATHwAYS 
UnDeRLYinG wORKinG MeMORY in THe 
mPFC
A number of biochemical and genetic studies have demonstrated 
that modulatory neurotransmission in the PFC is required 
for cognitive functions including working memory (11, 12, 
96, 122–125). Dopaminergic neurotransmission in the PFC 
has been shown to be important for working memory in both 
animals and human beings (126–134). Regional depletion of 
PFC dopamine causes profound working memory impairments 
in monkeys (126) and rats (127). Iontophoretic application of 
dopamine into the PFC for working memory tasks has revealed 
an increase of delay-period activity in monkeys (134). During 
working memory, the dopamine level is transiently increased in 
the PFC of both rats and human beings (135, 136). Explained 
briefly, dopamine receptors are divided into two families (D1 
and D2 class) based on second messenger coupling and ligand 
binding (137, 138); D1 class, composed of D1 and D5 dopamine 
receptors, increases the cAMP levels, whereas D2 class, composed 
of D2, D3, and D4 receptors, decreases cAMP levels (139, 140). 
The influence of dopamine in prefrontal neurons is largely medi-
ated by D1 dopamine receptors as they are much more abundant 
compared to D2 dopamine receptors in PFC pyramidal cells 
(141). The PFC D1 dopamine receptors are decreased in patients 
with schizophrenia (133). A D1 antagonist is able to suppress 
PFC delay-period activity. Similarly, the infusion of D1-specific 
agonists has further confirmed the importance of D1 dopamine 
receptors in the PFC with improved working memory (125, 142). 
Furthermore, the importance of D1 dopamine receptors has been 
investigated in non-human primates during delayed-response 
paradigms showing that working memory requires appropriate 
D1 receptor activation in the DLPFC (126, 129, 130, 142, 143). 
Taken together, these observations suggest that altered dopamine 
transmission at D1 receptors in DLPFC could be involved in the 
pathophysiology of working memory in schizophrenia (90, 95, 
144, 145).
In addition to dopamine receptors involved in working 
memory, other modulatory neurotransmitters, such as norepi-
nephrine (NE) acting through α-adrenergic receptors (146, 147), 
serotonin through 5-HT2A receptors (124), and acetylcholine 
through mAChRs (148) have been shown to be involved in 
working memory. Moderate levels of NE activate α2A adrenergic 
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receptors and result in improved working memory; however, at 
higher levels, NE activates α1 receptors, resulting in impaired 
working memory (123, 149, 150). Similarly, it has been pro-
posed that excessive prefrontal NE levels may contribute to the 
working memory deficits in schizophrenia (122). Investigation 
of M1 mAChRs knockout mice has provided evidence that M1 
mAChRs are critical for the performance of non-matching-to-
sample working memory tasks (151).
Several lines of research have indirectly indicated that Gq 
signaling pathways are implicated in working memory (12, 59, 
124, 130). In detail, translocation of the α subunit of Gq proteins 
from the membrane to a cytosolic fraction can be used as an 
indicator of activation (152). Gq translocates during the delay 
period of the match-to-place task for working memory (125), 
suggesting that the Gq signaling cascade is activated during 
working memory. Consistently, alterations in prefrontal Gq 
signalings have been associated with working memory deficits 
in patients with schizophrenia (153). RGS4, an inhibitor of Gq 
protein-induced intracellular Ca2+ release, is downregulated in 
PFC of schizophrenia mouse model (58, 154).
COnCLUSiOn AnD FUTURe ReMARKS
Although continued investigation is required to fully understand 
PLC-β1 hypofunction in the pathogenesis of schizophrenia, 
the results obtained to date suggest some challenges in the 
treatments for working memory deficits in schizophrenia. As 
indicated previously, altered expression of PLC-β1 has been 
detected in several brain regions of patients with schizophrenia 
including DLPFC (52, 53, 155–158). The major schizophrenia 
symptoms (1–6), such as negative and cognitive symptoms, have 
been observed in the behavioral characterization of PLC-β1−/− 
mice. These results indicate that disrupted PLC-β1 signaling 
in specific brain regions can be relevant to the pathogenesis of 
schizophrenia (55–58).
Furthermore, neurotransmitter transmissions such as dopa-
mine through D1 receptors coupled to PLC in the mPFC (129, 
141, 159, 160), NE acting through α-adrenoreceptors (146, 147), 
serotonin through 5-HT2A receptors (124), and acetylcholine 
through M1 mAChRs (148) are necessary for working memory. 
The activities of intracellular second messenger pathways linked 
with PLC in the mPFC are also critical for working memory 
(161–163). In addition, PLC-β1 knockdown and impaired work-
ing memory in the mPFC have been discussed in this review, 
suggesting that the mPFC-specific PLC-β1 pathways underlying 
working memory could be different from those for anxiety or 
other schizophrenia endophenotypes of PLC-β1−/− mice (59).
In conclusion, these results support the notion that the decrease 
in PLC-β1 expression in the brains of patients with schizophrenia 
is a pathogenically relevant molecular marker of the disorder 
(54, 56–59). This interpretation offers new insight into PLC-β1 
hypofunction in the pathogenesis of schizophrenia and may aid 
in a better understanding of the neural mechanisms underlying 
working memory deficits in schizophrenia. Finally, PLC-β1 is 
not detected in a peripheral area (164, 165). Thus, PLC-β1 KO 
could not affect obesity or weight gain. PLC-β1 KO mice are even 
not hypophagic and lean unlike M3 KO mice (65). Therefore, the 
PLC-β1-based treatments are necessary for the development of 
novel psychotherapeutic approaches with reducing metabolic 
side effects.
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